

~ Updates on HPMS Memos ~

<b>CMS Memo Title &amp; Release Date</b>	Technical Assistance Opportunities for MMPs and other Medicare Organizations Serving Dually Eligible Beneficiaries – Dated 12/18/2020
<b>Summary</b>	HPMS offers an opportunity regarding health plans to improve the quality of care for dually eligible individuals. These virtual meetings will focus on strategies organizations may use to connect with hard-to-reach members and engage them in primary and specialist care, social services, and long-term services. The application link is included in the memo. The deadline to apply is <b>January 11<sup>th</sup>, 2021</b> .
<b>Action</b>	Applicable to PACE. Refer to memo for complete details.
<b>CMS Memo Title &amp; Release Date</b>	PART D Qualified Independent Contractor (QIC) Contract Award Notification - C2C Innovative Solutions, Inc. will be the Part D QIC beginning February 1, 2021. – Dated 12/18/2020
<b>Summary</b>	CMS announces that C2C Innovative Solutions (C2C) was awarded the Part D Qualified Independent Contractor (QIC) contract on November 17, 2020. Effective February 1, 2021, C2C will be responsible for conducting reconsiderations under the Medicare Part D Program.
<b>Action</b>	Informational to PACE. Refer to memo for complete details.
<b>CMS Memo Title &amp; Release Date</b>	CY 2021 Formulary Information – Dated 12/21/2020
<b>Summary</b>	CMS released the process for submitting formulary updates for CY 2021. Sponsors are reminded that the earliest effective date to implement approved negative formulary changes is March 1, 2021. Negative formulary change requests could be submitted via HPMS NCR beginning now through October 1 <sup>st</sup> , 2021. Only approved negative changes may be implemented.
<b>Action</b>	Applicable to PACE plans that maintain and submit a formulary to CMS. Refer to the memo for complete dates on the formulary update process.
<b>CMS Memo Title &amp; Release Date</b>	Contract Year 2022 Model of Care Training – Dated 12/22/2020
<b>Summary</b>	CMS releases training on contract year 2022 Model of Care (MOC) submission requirements for sponsors offering a Special Needs Plan. MOC Submission are due in HPMS by February 17 <sup>th</sup> , 2021 8PM. Links and invites are included in the memo.
<b>Action</b>	Applicable to PACE plans that offer a Special Needs Plan. Refer to memo for the invite and links.

<b>CMS Memo Title &amp; Release Date</b>	Reporting of Emergency Part C & D Issues for January 1 through January 3, 2021 – Dated 12/23/2020
<b>Summary</b>	CMS has established a Part C & D operations monitoring program for non-technical significant emergency issues for January 1 through January 3, 2021. Plan sponsors are to report issues that arise to both CMS and the plan’s CMS Account Manager. CMS also request plans to update their CEO and Emergency Contact Information in HPMS by December 28, 2020.
<b>Action</b>	Applicable to PACE. Refer to the memo for complete details on distinguishing reportable issues and how to report through this process.
<b>CMS Memo Title &amp; Release Date</b>	Announcement of the December 2020 Encounter Data Software Release Updates – Dated 12/23/2020
<b>Summary</b>	CMS has implemented another software improvement to the systems related to accepted and processing encounter data. Edit 22395 has been adjusted from a reject to informational effective 12/18/2020.
<b>Action</b>	Applicable to PACE. Refer to memo for complete details.
<b>CMS Memo Title &amp; Release Date</b>	2021 PACE and Medicare Parts C and D Program Audits – Dated 12/23/2020
<b>Summary</b>	CMS has compiled a list of questions/answers about how routine audit activities for PACE and Medicare Parts C and D organizations in 2021 will proceed during the ongoing Public Health Emergency (PHE).
<b>Action</b>	Applicable to PACE. Refer to memo for complete details.
<b>CMS Memo Title &amp; Release Date</b>	2021 Part D Drug Management Program Guidance – Dated 12/23/2020
<b>Summary</b>	CMS releases an updated memorandum regarding contract year (CY) 2021 Drug Management Programs (DMPs). Updates and changes are in red italicized font.
<b>Action</b>	Applicable to PACE plans who implemented a Drug Management Program (DMP). Refer to the memo for complete details on the updates
<b>CMS Memo Title &amp; Release Date</b>	Contract Year 2021 Coronavirus Disease 2019 (COVID-19) Permissive Actions FAQ – Dated 12/28/2020
<b>Summary</b>	CMS releases a memo of FAQs which address continued application of certain enforcement discretion policies and reiterate certain guidance in light of the continuation of the COVID-19 Public Health Emergency (PHE) into 2021.
<b>Action</b>	Refer to memo for complete details.
<b>CMS Memo Title &amp; Release Date</b>	Healthcare Effectiveness Data and Information Set (HEDIS) Measurement Year (MY) 2020 Patient-Level Detail (PLD) Data File Submission Information – Dated 12/28/2020

<b>Summary</b>	This memorandum describes the data file submission process for HEDIS Measurement Year (MY) 2020 Patient-Level Detail (PLD). Sponsors must submit their HEDIS PLD data to CMS by <b>11:59 p.m., Eastern Time, June 15, 2021.</b>
<b>Action</b>	Informational to PACE.
<b>CMS Email Title &amp; Release Date</b>	Coverage Gap Discount Program: January Participating Labeler Codes - Dated 12/28/2020
<b>Summary</b>	<p>CMS will update the manufacturer labeler codes for the Coverage Gap Discount Program by January 1<sup>st</sup>, 2021. The update includes the following to be added:</p> <ul style="list-style-type: none"> <li>• 73511 Acasti Pharma Inc.</li> <li>• 73606 Apellis Pharmaceuticals, Inc.</li> <li>• 73210 Aurinia Pharmaceuticals inc.</li> <li>• 68418 Biocodex</li> <li>• 72769 BioCryst Pharmaceuticals, Inc.</li> <li>• 73556 ChemoCentryx, Inc.</li> <li>• 73207 Deciphera Pharmaceuticals, LLC</li> <li>• 71879 EyePoint Pharmaceuticals</li> <li>• 72356 Foamix Pharmaceuticals Inc.</li> <li>• 61476 Green Cross Corporation</li> <li>• 74676 Verity Pharmaceuticals Inc.</li> <li>• 73535 MorphoSys US</li> <li>• 72974 Myovant</li> <li>• 73070 Novo Nordisk Pharma, Inc.</li> <li>• 73292 NS Pharma, Inc.</li> <li>• 73657 Oncopeptides Inc</li> <li>• 73521 Oyster Point Pharma, Inc</li> <li>• 72305 Provell Pharmaceuticals LLC</li> <li>• 73116 Secura Bio, Inc</li> <li>• 72694 Servier Pharmaceuticals LLC</li> <li>• 73127 Zosano Pharma</li> </ul> <p>Deleted:</p> <ul style="list-style-type: none"> <li>• 72401 Solus RX, LLC</li> </ul>
<b>Action</b>	Although the Coverage Gap Discount Program does not apply to PACE, the participating labeler codes are applicable because only brand name prescriptions with NDCs from these codes are accepted for Part D payment. Pharmastar has made the necessary software adjustments to accommodate for the updated codes.
<b>CMS Email Title &amp; Release Date</b>	Medicare Advantage/Prescription Drug System (MARx) January 2021 Payment – INFORMATION – Dated 12/29/2020

<b>Summary</b>	CMS provided information about the January payment which is scheduled for January 4, 2021 and may require plan action: <ul style="list-style-type: none"> <li>• National Medicare Education Campaign (NMEC) User Fees for 2021</li> <li>• Coordination of Benefits (COB) User Fees for 2021</li> <li>• 2021 Frailty Score Update</li> <li>• Sequestration</li> <li>• Changes to MARx Plan Transaction Processing</li> </ul>
<b>Action</b>	Informational to PACE. Refer to the memo for complete details and items that may be applicable to your plan.
<b>CMS Memo Title &amp; Release Date</b>	Completion of the Reopening of the 2015 Final Part D Payment Reconciliation – Dated 12/29/2020
<b>Summary</b>	CMS completed the calculations for the reopening of the 2015 Final Part D Payment Reconciliation. Any payment adjustments from the results of the calculations will be reflected in the March 2021 payment. Plans can retrieve the payment reconciliation reports on the CSSC website on February 1 <sup>st</sup> , 2021.
<b>Action</b>	Applicable to PACE. Refer to the memo for complete details and how to access the reports.

For the latest CMS response to COVID-19, please visit the CMS.gov website.

### Request for Timely Enrollment Updates

Due to the upcoming holidays, Pharmastar is asking plan Enrollment Departments to send any member enrollment/disenrollment and changes, if it is available, as timely as possible. Please forward this information to your organization’s Enrollment Department along with the Pharmastar email address: [enrollment@pharmastarpbm.com](mailto:enrollment@pharmastarpbm.com).

### Important Date Reminders

Date	Item
January 11 <sup>th</sup> , 2021	Application deadline to join the virtual ICCoP meetings.
December 31, 2020	2021 Readiness Checklist-review <i>and have all applicable items in place for 2021</i>
<i>*Subject to change, forthcoming information to be release by CMS.</i>	

Please note that this information is provided to you in summary form for general informational purposes only and does not constitute legal or regulatory compliance advice. It is your responsibility to consult with your Compliance Officer and/or legal counsel to determine applicability of any regulation or standards referenced herein to your organization and/or processes.